Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) — Form 144: Proposed sale of shares
AI-generated summary
Director Christine Poon of Regeneron Pharmaceuticals, Inc. proposes to sell 7,830 shares of Common Stock with an aggregate market value of $7,526,665.80. The shares were originally acquired as compensation through stock options on January 3, 2018, January 3, 2019, and January 3, 2020. The sale is planned through Goldman Sachs & Co. LLC on or about November 2, 2026.
Key facts
- Seller
- Christine Poon
- Relationship
- Director
- Shares to sell
- 7,830
- Market value
- $7,526,665.80
- Approximate sale date
- Nov 2, 2026
- Broker
- Goldman Sachs & Co. LLC
- Acquired (1)
- Jan 3, 2018 · Acquired as compensation -- Stock Options
- Acquired (2)
- Jan 3, 2019 · Acquired as compensation -- Stock Options
- Acquired (3)
- Jan 3, 2020 · Acquired as compensation -- Stock Options
More REGN filings
- 144
Filed Nov 2, 2026
- 144
Filed Nov 2, 2026
- 144
Filed Oct 30, 2026
- 144
Filed Oct 30, 2026
- 144
Filed Oct 30, 2026
- 10-Q
Filed Oct 30, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.